Using a nitrocefin competition assay, I determined the relative substrate affinity index (RSAI) values of nine clinically significant beta-lactamase enzymes against a range of beta-lactams. Using selected beta-lactam substrates, I observed large differences in the RSAI values of the nine enzymes that were sufficient in many cases to positively identify specific enzymes. I made use of the unique RSAI values of SHV-1, TEM-1, and TEM-2 beta lactamases with cefoxitin to screen for the presence of these enzymes in Klebsiella aerogenes clinical isolates. The RSAI values also allow for the prediction of the outcome of beta-lactam therapy against specific beta-lactamase-producing isolates.
Resistance to beta-lactam antibiotics is now widespread among many bacterial genera. The most common mechanism of resistance is the production of beta-lactamases, enzymes which hydrolyze the beta-lactam ring and inactivate antibiotics. Although many gram-negative bacteria produce inducible, chromosomally coded beta-lactamases, in all but a few cases their role in resistance to beta-lactams appears to be open to doubt. In gram-negative bacteria, several constitutive, plasmid-coded beta-lactamases have been identified on the basis of their substrate profiles against a range of beta-lactams and their isoelectric points (5) . A variety of methods is available to determine substrate profiles (6), but they suffer from a number of disadvantages. For example, hydrolysis of penicillins and cephalosporins may be monitored by a fall in UV absorption at a wavelength characteristic of each beta-lactam used, but it is readily apparent that relatively pure enzyme preparations have to be used in such assays to reduce background absorption. In addition to being laborious to perform, many of the assay methods are insensitive. Although capable of detecting gross differences in relative hydrolysis rates of beta-lactams, substrate profiles often fail to distinguish between a low rate of hydrolysis due to a low affinity of the enzyme for the substrate and one due to enzyme inhibition by the substrate. This distinction is becoming more important with the introduction of beta-lactamase inhibitors, such as clavulanic acid.
Given the large differences in the hydrolysis rates of beta-lactams by different beta-lactamases, it is possible to predict that many betalactams are likely to be ineffective in vivo against a pathogen producing specific beta-lactamases. Although a mass of evidence is available on the trends of antibiotic susceptibility of clinical isolates (1) , little practical information is available on the contribution of specific betalactamases, largely because of the difficulty of identification. The problem cannot be ignored, however, because beta-lactam antibiotics constitute our principal defense against pathogenic bacteria, and a policy for sensible antibiotic use depends upon the avoidance of over-prescription of the newer cephalosporins when an older (and cheaper) beta-lactam would be effective. It is impractical to test every clinical isolate against every possible beta-lactam and all possible combinations of beta-lactamase inhibitors and beta-lactams; therefore, a data base of the sensitivity of specific beta-lactamase-producing clinical isolates to a range of beta lactams is needed.
I have developed a very sensitive assay which allows the quantitation of the relative affinities of beta-lactamases for beta-lactam antibiotics. The assay is rapid, simple to perform, and amenable to automation. It yields a wealth of information on the interactions between betalactamases and their substrates which is useful in the prediction of successful beta-lactam therapy. Differences in relative affinities of a variety of clinically important beta-lactamases now also allow simple beta-lactamase identification and, in some cases, even bacterial identification. 
MATERIALS AND METHODS

RESULTS
Determination of RSAI values. The chromogenic substrate nitrocefin is readily cleaved by all of the beta-lactamases I used. Beta-lactam antibiotics which are substrates of a beta-lactamase enzyme readily compete with nitrocefin in my assay. The effect of various concentrations of ampicillin on the cleavage of nitrocefin by TEM-2 is shown in Fig. 1A . From a plot of percent nitrocefin cleavage against ampicillin concentration, the ampicillin concentration which results in 50% inhibition of the activity of TEM-2 ( Fig. 1B) can be determined. This ampicillin concentration is a direct estimate of the relative affinity of TEM-2 for ampicillin and nitrocefin. For ease of comparison of the affinity values of a specific beta-lactamase against different beta-lactam antibiotics, I propose the term relative substrate affinity index (RSAI), which is the ratio of the beta-lactam concentration giving 50% inhibition of nitrocefin cleavage to the nitrocefin concentration used in the assay. In the case of ampicillin, the RSAI value is 1.3.
The effect of competition by beta-lactams on nitrocefin cleavage kinetics also yields information on the mechanism of interaction between an antibiotic and a beta-lactamase. For example, most of the beta-lactams tested against TEM-2 show a pattern of inhibition similar to that of ampicillin (Fig. 1A) ; i.e., increasing the betalactam concentration reduces the rate of nitrocefin cleavage (shown as a reduced slope of the increase in OD486 value), but the plots are still linear. This is characteristic of competitive inhibition between ampicillin and nitrocefin. In con- nonlinear kinetics of nitrocefin cleavage inhibition (Fig. 2) . The same pattern of nitrocefin cleavage inhibition by TEM-2 was also observed with the beta-lactamase inhibitors clavulanic acid and CP 45,899 (data not shown) and with moxalactam and cefoxitin. Preincubation of TEM-2 with SQ 14,359 for 5 min before the addition of nitrocefin resulted in a significant reduction in nitrocefin cleavage (Fig. 2) typical of a beta-lactamase inhibitor. The RSAI values of nine clinically significant beta-lactamase enzymes against beta-lactams are shown in Table   1 .
It is perhaps not surprising that the chromosomal beta-lactamases of E. cloacae and Pseudomonas aeruginosa, which are classified as cephalosporinases, should exhibit very low RSAI values against most of the beta-lactams, in contrast to penicillinase enzymes like TEM-1 and SHV-1. However, the large differences in the RSAI values of the penicillinase enzymes with a single competing substrate were remarkable.
Beta-lactamase screening. The large differences in RSAI values of beta-lactamases against a single beta-lactam suggests that simple betalactamase screening may be feasible. I tested this with SHV-1, which has a uniquely high RSAI value of 600 against cefoxitin ( Table  2 . It is of interest that this enzyme does not exhibit nonlinear inhibition kinetics with any of the beta-lactams tested, in contrast to SHV-1. Cefoxitin at a concentration of 30 mg/ml is also useful to screen for the presence of TEM-1 or TEM-2, owing to the characteristic nonlinear inhibition kinetics of nitrocefin cleavage (Fig. 3) . I screened a large number of recent clinical isolates of K. aerogenes (Public Health Laboratory, Norwich, Norfolk, England) with cefoxitin. Over 60% exhibited the characteristic nonlinear inhibition kinetics of nitrocefin cleavage with cefoxitin. Isoelectric focusing with control SHV-1, TEM-1, and TEM-2 confirmed the presence of TEM-1 or TEM-2 in those isolates predicted from the above test. In all of the isolates which produced a TEM-type enzyme, we also detected SHV-1 on the isoelectric focusing gels when they were overloaded with respect to TEM-1 or TEM-2. A third example of the use of RSAI values in beta-lactamase identification involves an ampicillin-resistant isolate obtained from a water sample from the River Wensum next to the University of East Anglia, Norwich, Norfolk, England. After confirming the presence of a beta-lactamase which had an RSAI value of 0.02 against cefoxitin, I suspected the E. cloacae beta-lactamase. This suspicion was confirmed by determining the RSAI value of the extract against cephaloridine (RSAI value, 15.6) and that against clavulanic acid (RSAI value, 48). My identification of this river isolate as E. cloacae was confirmed by a blind bacterial identification test kindly performed for me by the Public Health Laboratory.
RSAI values and MICs. A high RSAI value implies that the beta-lactam is a poor substrate for that beta-lactamase. Therefore, in the absence of any permeability barrier to their penetration, beta-lactams should be clinically effec- tive against bacteria producing a beta-lactamase against which they exhibit high RSAI values in vitro. I tested this hypothesis by determining the MICs of a range of beta-lactams for E. coli C9RP4 and E. coli C9 ( Table 3) .
The penicillins which exhibited low RSAI values against TEM-2 in vitro were ineffective in vivo against E. coli C9RP4. In contrast, the new cephalosporins, such as ceftazidime, exhibited very high RSAI values and very low MICs. The use of isogenic strains, differing only in the presence of the plasmid coding for a beta-lactamase, is essential for interpretation of this experiment.
Using antibiotic sensitivity test disks, I tested my collection of recent clinical isolates of K. aerogenes, which produce TEM-1 or TEM-2, against cefoxitin and cefotaxime. All isolates were extremely sensitive to both of these antibiotics.
Many E. cloacae isolates are resistant to most beta-lactams, including the new cephalosporins (1). This resistance is presumably the result of the permeability barrier to beta-lactams in the E. cloacae outer membrane, together with the presence of a beta-lactamase enzyme. A comparison of the RSAI values of the E. cloacae enzyme with the MICs of the same beta-lactams for E. cloacae (Table 4) reveals that the lowest MIC is shown by moxalactam. Although the RSAI value of the E. cloacae enzyme against moxalactam is very low, implying that it would be readily destroyed by this enzyme, the nonlinear inhibition kinetics suggest that moxalactam could act as a combined beta-lactamase inhibitor and killing agent. I therefore predicted that a combination of moxalactam and a beta-lactam having a high RSAI value against this enzyme should be synergistic. This synergism is illustrated in Fig.  4 with cephaloridine and moxalactam. A similar but less effective synergy was observed between moxalactam and carbenicillin, mecillinam, cephazolin, cefoperazone, or cefoxitin. The absence of synergy with all other beta-lactams is illustrated by the results obtained with ampicillin and cefuroxime (Fig. 5) .
The synergistic action of moxalactam in combination with carbenicillin or cephaloridine was prolonged; no regrowth of E. cloacae was observed for at least 5 h after addition (Fig. 6 ). E. cloacae laboratory strains which have an inducible cephalosporinase are readily killed by many cephalosporins at concentrations of less than 10 ,ug/ml (data not shown). We are currently searching for further E. cloacae isolates which are constitutive cephalosporinase producers to test for synergy.
DISCUSSION
Determination of the RSAI values of betalactamase enzymes is relatively simple and requires neither a purified enzyme nor any detailed analysis of enzyme-substrate interactions. The nonlinear inhibition kinetics of nitrocefin cleavage are also very easy to detect. My findings with cefoxitin and the TEM-type enzymes are in agreement with those of a recent report (3), whereas the similar properties of SQ 14,359 have not been reported previously.
The very large differences in RSAI values between penicillinase and cephalosporinase enzymes were not unexpected; however, the ap- (0) were performed with the single beta-lactams alone. A, Cephaloridine (10 ,ug/ml); A, cefoxitin (10 FLg/ml); V, cephaloridine (10 pg/ml) plus cefoxitin (10 ,ug/ml); 0, moxalactam (5 ,g/ml); O, moxalactam (5 ,ug/ml) plus cefoxitin (10 ,ug/ml); *, moxalactam (5 ,ug/ml) plus cephaloridine (10 ,ug/ml). 0.02 against cefoxitin. The beta-lactamase was confirmed as the E. cloacae chromosomal betalactamase by further RSAI determinations, and my identification of the producing organism was subsequently proven independently. Such a bacterial identification is obviously possible only for chromosomally coded beta-lactamases, which are constitutively produced or have been induced by pregrowth with a beta-lactamase inducer.
RSAI values are a direct measure of the relative affinity of a beta-lactamase for nitrocefin and the competing beta-lactam. The affinity of beta-lactamase for a specific beta-lactam in vitro is, of course, only one component in the interaction of a number of factors which determine the clinical usefulness of individual beta-lactam antibiotics against beta-lactamase-producing bacteria. In addition to (i) the permeability properties of the outer cell membrane of gram-negative bacteria, (ii) the Km and Vm. values of the enzyme for that specific beta-lactam, and (iii) the amount of enzyme produced (9), one must also consider the affinity of the beta-lactam for its target, one or more of the penicillin-binding proteins (8) . It this regard, ceftizoxime and ceftazidime appear to be major breakthroughs; their RSAI values of 1,000 and 1,500, respectively, are the highest I have recorded against a range of 12 clinically significant beta-lactamases. These very high RSAI values also match the very low MICs of the same antibiotics for E. coli C9RP4. I am currently testing a series of isogenic E. coli strains which differ only by the presence of a plasmid-coded beta-lactamase to study further the correlation between RSAI values and MICs.
It is also encouraging that none of the K. aerogenes clinical isolates producing a TEMtype beta-lactamase show resistance to cefoxitin or cefotaxime.
Inspection of the RSAI values of a range of beta-lactams against the E. cloacae beta-lactamase suggested likely synergistic beta-lactams to use in combination in vivo against this constitutive, beta-lactamase-producing isolate. In vivo tests have supported the predictive value of the RSAI data. It would be surprising if the predictions of synergistic combinations effective against E. cloacae were absolutely reliable, given the impermeability of its outer membrane to many beta-lactam antibiotics (4); however, I am encouraged that the E. cloacae isolate recovered from the River Wensum was also susceptible to the same synergistic combinations (data not shown).
I am currently developing a panel of competing beta-lactams with the aim of providing a rapid, automated beta-lactamase identification assay. Such an assay would be invaluable in the further development of rational beta-lactam therapy.
